Cellectar Biosciences To Seek EMA Conditional Approval For Iopofosine I 131 In 3Q26; To Present Final CLOVER WaM Results, Advance CLR 125 Breast Cancer Study In 2026

+4.29%

Cellectar Biosciences

CLRB

3.65

+4.29%

Following Guidance from the European Medicines Agency's (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom's Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026

Plans to Present Final Results and Subset Analysis of WM Patients from the Phase 2 CLOVER WaM Clinical Study of Iopofosine I 131

Anticipates Dosing of First Patients in Phase 1b Study of CLR 125 for the Treatment of Triple Negative Breast Cancer in 1Q26 with Interim Data Mid-2026

FLORHAM PARK, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the development of targeted radiotherapeutics for cancer, today announces plans to highlight the company's 2026 strategic initiatives at the upcoming Biotech Showcase, taking place January 12-15, 2026, in San Francisco during the 44th Annual JP Morgan Healthcare Conference. James Caruso, president and CEO of Cellectar, will present a corporate update on Tuesday, January 14, 2025, at 1:30 pm Pacific Time.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.